ECSP20066271A - Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina d1 - Google Patents
Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina d1Info
- Publication number
- ECSP20066271A ECSP20066271A ECSENADI202066271A ECDI202066271A ECSP20066271A EC SP20066271 A ECSP20066271 A EC SP20066271A EC SENADI202066271 A ECSENADI202066271 A EC SENADI202066271A EC DI202066271 A ECDI202066271 A EC DI202066271A EC SP20066271 A ECSP20066271 A EC SP20066271A
- Authority
- EC
- Ecuador
- Prior art keywords
- pirazo
- dopamine
- receptor
- positive modulators
- tetrahydroisoquinoline derivatives
- Prior art date
Links
- 102000004076 Dopamine D1 Receptors Human genes 0.000 title 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 title 1
- OEDUIFSDODUDRK-UHFFFAOYSA-N 5-phenyl-1h-pyrazole Chemical compound N1N=CC=C1C1=CC=CC=C1 OEDUIFSDODUDRK-UHFFFAOYSA-N 0.000 abstract 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical class CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona ciertos compuestos de (fenil)-(pirazol)-3,4-dihidroisoquinolin-2(1H)-il)etan-1-ona de la Fórmula I como moduladores alostéricos positivos (PAM) D1 y composiciones farmacéuticas de estos. La invención proporciona además métodos para usar un compuesto de la Fórmula I, o una sal de este aceptable desde el punto de vista farmacéutico, para tratar ciertos síntomas de la enfermedad de Parkinson, la esquizofrenia, el ADHD o la enfermedad de Alzheimer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862660622P | 2018-04-20 | 2018-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20066271A true ECSP20066271A (es) | 2020-11-30 |
Family
ID=66324031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202066271A ECSP20066271A (es) | 2018-04-20 | 2020-10-19 | Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina d1 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10611751B2 (es) |
| EP (1) | EP3781560B1 (es) |
| JP (1) | JP7083916B2 (es) |
| KR (1) | KR102520872B1 (es) |
| CN (1) | CN111971282B (es) |
| AR (1) | AR114467A1 (es) |
| AU (1) | AU2019256350B2 (es) |
| BR (1) | BR112020019934A2 (es) |
| CA (1) | CA3097692C (es) |
| CL (1) | CL2020002697A1 (es) |
| CO (1) | CO2020012678A2 (es) |
| CR (1) | CR20200481A (es) |
| EA (1) | EA202092146A1 (es) |
| EC (1) | ECSP20066271A (es) |
| ES (1) | ES2927142T3 (es) |
| IL (1) | IL278045B2 (es) |
| JO (1) | JOP20200263A1 (es) |
| MA (1) | MA52286A (es) |
| MX (1) | MX2020010914A (es) |
| MY (1) | MY197645A (es) |
| NZ (1) | NZ767900A (es) |
| PE (1) | PE20201151A1 (es) |
| PH (1) | PH12020551713A1 (es) |
| SA (1) | SA520420382B1 (es) |
| SG (1) | SG11202009938TA (es) |
| TW (1) | TWI725408B (es) |
| UA (1) | UA125271C2 (es) |
| WO (1) | WO2019204418A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA56445A (fr) | 2019-07-01 | 2022-05-11 | UCB Biopharma SRL | Dérivé de tétrahydroisoquinoléine substitué utilisé comme modulateur allostérique positif de d1 |
| AU2020299953A1 (en) | 2019-07-01 | 2022-01-06 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator |
| US20240083875A1 (en) | 2020-12-18 | 2024-03-14 | UCB Biopharma SRL | Dihydroisoquinolinyl derivatives |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68910999T2 (de) | 1988-02-19 | 1994-03-24 | Smithkline Beecham Farma | 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten. |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| DE60115227T2 (de) | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| US7601739B2 (en) | 2003-08-08 | 2009-10-13 | Virgina Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases |
| AR095883A1 (es) | 2013-04-18 | 2015-11-18 | Astellas Pharma Inc | Compuestos de acetamida heterocíclica |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| SI3204359T1 (sl) | 2014-10-08 | 2020-10-30 | UCB Biopharma SRL | Tetrahidroizokinolinski derivati |
| TR201908151T4 (tr) | 2014-10-08 | 2019-06-21 | Ucb Biopharma Sprl | İzoindolin türevleri. |
| AR105025A1 (es) | 2015-06-19 | 2017-08-30 | Astellas Pharma Inc | Compuesto de imidazodiazepina |
| AR106332A1 (es) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona |
| EP3442945B1 (en) | 2016-04-13 | 2020-07-08 | UCB Biopharma SRL | Tetrahydroisoquinoline derivatives |
| EP3418270A1 (en) | 2017-06-19 | 2018-12-26 | Universidad Complutense De Madrid | Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor |
| EP3762383B1 (en) | 2018-03-06 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Positive allosteric modulators of dopamine 1 receptor and method of use thereof |
-
2019
- 2019-04-03 TW TW108111844A patent/TWI725408B/zh active
- 2019-04-04 AR ARP190100882A patent/AR114467A1/es unknown
- 2019-04-17 KR KR1020207029608A patent/KR102520872B1/ko active IP Right Grant
- 2019-04-17 UA UAA202005900A patent/UA125271C2/uk unknown
- 2019-04-17 JP JP2020557950A patent/JP7083916B2/ja active Active
- 2019-04-17 CA CA3097692A patent/CA3097692C/en active Active
- 2019-04-17 ES ES19720352T patent/ES2927142T3/es active Active
- 2019-04-17 CN CN201980027079.8A patent/CN111971282B/zh active Active
- 2019-04-17 JO JOP/2020/0263A patent/JOP20200263A1/ar unknown
- 2019-04-17 MX MX2020010914A patent/MX2020010914A/es unknown
- 2019-04-17 EP EP19720352.4A patent/EP3781560B1/en active Active
- 2019-04-17 BR BR112020019934-6A patent/BR112020019934A2/pt unknown
- 2019-04-17 AU AU2019256350A patent/AU2019256350B2/en active Active
- 2019-04-17 EA EA202092146A patent/EA202092146A1/ru unknown
- 2019-04-17 NZ NZ767900A patent/NZ767900A/en unknown
- 2019-04-17 MY MYPI2020005419A patent/MY197645A/en unknown
- 2019-04-17 CR CR20200481A patent/CR20200481A/es unknown
- 2019-04-17 MA MA052286A patent/MA52286A/fr unknown
- 2019-04-17 WO PCT/US2019/027842 patent/WO2019204418A1/en active Application Filing
- 2019-04-17 IL IL278045A patent/IL278045B2/en unknown
- 2019-04-17 SG SG11202009938TA patent/SG11202009938TA/en unknown
- 2019-04-17 PE PE2020001478A patent/PE20201151A1/es unknown
- 2019-04-17 US US16/386,684 patent/US10611751B2/en active Active
-
2020
- 2020-10-09 PH PH12020551713A patent/PH12020551713A1/en unknown
- 2020-10-13 CO CONC2020/0012678A patent/CO2020012678A2/es unknown
- 2020-10-16 CL CL2020002697A patent/CL2020002697A1/es unknown
- 2020-10-19 EC ECSENADI202066271A patent/ECSP20066271A/es unknown
- 2020-10-19 SA SA520420382A patent/SA520420382B1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20066271A (es) | Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina d1 | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| MX2021010306A (es) | Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso. | |
| MX2021013564A (es) | Gamma-carbolinas fusionadas con heterociclo deuterado. | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| MX2020000968A (es) | Compuestos organicos. | |
| MX2020000967A (es) | Compuestos organicos. | |
| MX2021014508A (es) | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. | |
| EA201591291A1 (ru) | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| NI202100012A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| SA518390920B1 (ar) | مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| CO2021001849A2 (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| BR112016017816A8 (pt) | derivados de etinila, seus usos, e composição farmacêutica | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| MA41975B1 (fr) | Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer | |
| AR125853A2 (es) | Composición farmacéutica de una sal hemisulfato de un compuesto nucleotídico |